title: Precision medicine in oncology standard of care.
abstract: OBJECTIVE
  To review the histologic subtypes and staging of non-small cell lung cancer and metastatic melanoma, as well as the molecular markers used to direct standard therapy.
  
  
  METHODS
  Book chapters and journal articles from medical and nursing literature, as well as published clinical guidelines.
  
  
  CONCLUSIONS
  Patients with metastatic non-small cell lung cancer and metastatic melanoma have had a paucity of treatment options, most fraught with toxicity with limited benefit. Increased understanding of tumor genetics and molecular markers has expanded the treatment options for these patients, often providing them with durable responses and improved quality of life.
  
  
  CONCLUSIONS
  To provide education and support to their patients, nurses caring for these patients need to understand the role that genetics and molecular markers play in directing these therapies.
authors.forename: Lynn
authors.initials: L
authors.lastname: Adams
mesh_terms: D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000451:nursing*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000451:nursing*; D008545:Melanoma / Q000188:drug therapy / Q000451:nursing*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000451:nursing*; D009362:Neoplasm Metastasis; D009859:Oncology Nursing / Q000379:methods*; D018802:Patient-Centered Care / Q000379:methods; D057285:Precision Medicine / Q000379:methods / Q000451:nursing*
chemical_list: D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents
keywords: Precision medicine; molecular targets; oncology standard of care